183 related articles for article (PubMed ID: 28245129)
1. Effect of Dye and Conjugation Chemistry on the Biodistribution Profile of Near-Infrared-Labeled Nanobodies as Tracers for Image-Guided Surgery.
Debie P; Van Quathem J; Hansen I; Bala G; Massa S; Devoogdt N; Xavier C; Hernot S
Mol Pharm; 2017 Apr; 14(4):1145-1153. PubMed ID: 28245129
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of [
Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
[TBL] [Abstract][Full Text] [Related]
3. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging.
Lee SB; Hassan M; Fisher R; Chertov O; Chernomordik V; Kramer-Marek G; Gandjbakhche A; Capala J
Clin Cancer Res; 2008 Jun; 14(12):3840-9. PubMed ID: 18559604
[TBL] [Abstract][Full Text] [Related]
4. Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer.
Xiao Y; Mei C; Xu D; Yang F; Yang M; Bi L; Mao J; Pang P; Li D
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2305-2318. PubMed ID: 36914753
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT.
Zeven K; De Groof TWM; Ceuppens H; Awad RM; Ertveldt T; de Mey W; Meeus F; Raes G; Breckpot K; Devoogdt N
Front Immunol; 2023; 14():1268900. PubMed ID: 37799715
[TBL] [Abstract][Full Text] [Related]
6. The GEM-handle as convenient labeling strategy for bimodal single-domain antibody-based tracers carrying
Declerck NB; Huygen C; Mateusiak L; Stroet MCM; Hernot S
Front Immunol; 2023; 14():1285923. PubMed ID: 38035094
[TBL] [Abstract][Full Text] [Related]
7. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
[TBL] [Abstract][Full Text] [Related]
8. Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma.
Day KE; Beck LN; Deep NL; Kovar J; Zinn KR; Rosenthal EL
Laryngoscope; 2013 Nov; 123(11):2681-9. PubMed ID: 23616260
[TBL] [Abstract][Full Text] [Related]
9. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
[TBL] [Abstract][Full Text] [Related]
10. Validation of nanobody and antibody based in vivo tumor xenograft NIRF-imaging experiments in mice using ex vivo flow cytometry and microscopy.
Bannas P; Lenz A; Kunick V; Fumey W; Rissiek B; Schmid J; Haag F; Leingärtner A; Trepel M; Adam G; Koch-Nolte F
J Vis Exp; 2015 Apr; (98):e52462. PubMed ID: 25867711
[TBL] [Abstract][Full Text] [Related]
11. A thiopyrylium salt for PET/NIR-II tumor imaging and image-guided surgery.
Zhang X; Ding B; Qu C; Li H; Sun Y; Gai Y; Chen H; Fang H; Qian K; Zhang Y; Cheng Z; Lan X
Mol Oncol; 2020 May; 14(5):1089-1100. PubMed ID: 32191387
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging.
Chernomordik V; Hassan M; Lee SB; Zielinski R; Gandjbakhche A; Capala J
Mol Imaging; 2010 Aug; 9(4):192-200. PubMed ID: 20643022
[TBL] [Abstract][Full Text] [Related]
13. Near-infrared dye IRDye800CW-NHS coupled to Trastuzumab for near-infrared II fluorescence imaging in tumor xenograft models of HER-2-positive breast cancer.
Xiao J; Qiu S; Ma Q; Bai S; Guo X; Wang L
J Mater Chem B; 2023 Nov; 11(44):10738-10746. PubMed ID: 37929679
[TBL] [Abstract][Full Text] [Related]
14. Cadherin 17 Nanobody-Mediated Near-Infrared-II Fluorescence Imaging-Guided Surgery and Immunotoxin Delivery for Colorectal Cancer.
Ding Y; Zhou R; Shi G; Jiang Y; Li Z; Xu X; Ma J; Huang J; Fu C; Zhou H; Wang H; Li J; Dong Z; Yu Q; Jiang K; An Y; Liu Y; Li Y; Yu L; Li Z; Zhang X; Wang J
Biomater Res; 2024; 28():0041. PubMed ID: 38911825
[TBL] [Abstract][Full Text] [Related]
15. HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.
Altunay B; Morgenroth A; Beheshti M; Vogg A; Wong NCL; Ting HH; Biersack HJ; Stickeler E; Mottaghy FM
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1371-1389. PubMed ID: 33179151
[TBL] [Abstract][Full Text] [Related]
16. eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors.
Chapeau D; Beekman S; Handula M; Murce E; de Ridder C; Stuurman D; Seimbille Y
EJNMMI Radiopharm Chem; 2024 May; 9(1):44. PubMed ID: 38775990
[TBL] [Abstract][Full Text] [Related]
17. Selective Targeting of Nanobody-Modified Gold Nanoparticles to Distinct Cell Types.
Lee YH; Medhi H; Liu X; Ha IH; Nam KT; Ploegh H
ACS Appl Mater Interfaces; 2023 Dec; 15(51):59258-59268. PubMed ID: 38091481
[TBL] [Abstract][Full Text] [Related]
18. Preclinical assessment of IRDye800CW-labeled gastrin-releasing peptide receptor-targeting peptide for near infrared-II imaging of brain malignancies.
Zhang Y; Wang L; Zhang C; Zhang J; Yuan L; Jin S; Zhou W; Guan X; Kang P; Zhang C; Tian J; Chen X; Li D; Jia W
Bioeng Transl Med; 2023 Jul; 8(4):e10532. PubMed ID: 37476052
[TBL] [Abstract][Full Text] [Related]
19. Generation and Characterization of Novel Pan-Cancer Anti-uPAR Fluorescent Nanobodies as Tools for Image-Guided Surgery.
Mateusiak Ł; Floru S; De Groof TWM; Wouters J; Declerck NB; Debie P; Janssen S; Zeven K; Puttemans J; Vincke C; Breckpot K; Devoogdt N; Hernot S
Adv Sci (Weinh); 2024 Jun; ():e2400700. PubMed ID: 38845188
[TBL] [Abstract][Full Text] [Related]
20. Site-specifically radiolabeled nanobodies for imaging blood-brain barrier penetration and targeting in the brain.
Li Y; Wang J
J Labelled Comp Radiopharm; 2023 Dec; 66(14):444-451. PubMed ID: 37873934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
